Page 632 - Read Online

Page 20 of 24 Peyvandi et al. J Cancer Metastasis Treat 2019;5:44 I http://dx.doi.org/10.20517/2394-4722.2019.16

116. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer
2010;46:1181-8.
117. Walker ND, Patel J, Munoz JL, Hu M, Guiro K, et al. The bone marrow niche in support of breast cancer dormancy. Cancer Lett
2016;380:263-71.
118. Korah R, Boots M, Wieder R. Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for
breast cancer dormancy in bone marrow. Cancer Res 2004;64:4514-22.
119. Wheeler SE, Clark AM, Taylor DP, Young CL, Pillai VC, et al. Spontaneous dormancy of metastatic breast cancer cells in an all human
liver microphysiologic system. Br J Cancer 2014;111:2342-50.
120. Clark AM, Wheeler SE, Young CL, Stockdale L, Shepard Neiman J, et al. A liver microphysiological system of tumor cell dormancy and
inflammatory responsiveness is affected by scaffold properties. Lab Chip 2016;17:156-68.
121. El Touny LH, Vieira A, Mendoza A, Khanna C, Hoenerhoff MJ, et al. Combined SFK/MEK inhibition prevents metastatic outgrowth of
dormant tumor cells. J Clin Invest 2014;124:156-68.
122. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol
2013;15:807-17.
123. Sriram R, Lo V, Pryce B, Antonova L, Mears AJ, et al. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-
positive molecular apocrine-like tumors with reduced Notch1 activity. Breast Cancer Res 2015;17:7.
124. Pontier SM, Muller WJ. Integrins in breast cancer dormancy. APMIS 2008;116:677-84.
125. Barkan D, Chambers AF. beta1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res
2011;17:7219-23.
126. Sosa MS, Bragado P, Debnath J, Aguirre-Ghiso JA. Regulation of tumor cell dormancy by tissue microenvironments and autophagy. Adv
Exp Med Biol 2013;734:73-89.
127. Aqbi HF, Tyutyunyk-Massey L, Keim RC, Butler SE, Thekkudan T, et al. Autophagy-deficient breast cancer shows early tumor
recurrence and escape from dormancy. Oncotarget 2018;9:22113-22.
128. Tierney MT, Sacco A. Inducing and evaluating skeletal muscle injury by notexin and barium chloride. Methods Mol Biol 2016;1460:53-
60.
129. Agudo J, Park ES, Rose SA, Alibo E, Sweeney R, et al. Quiescent tissue stem cells evade immune surveillance. Immunity 2018;48:271-
85.e5.
130. Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol 2010;10:201-9.
131. Aguirre-Ghiso JA. How dormant cancer persists and reawakens. Science 2018;361:1314-5.
132. Hayflick L. The biology of human aging. Am J Med Sci 1973;265:432-45.
133. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003;63:2705-15.
134. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001;11:S27-31.
135. Campisi J. Cell biology: the beginning of the end. Nature 2014;505:35-6.
136. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013;75:685-705.
137. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of
Cip1 in normal human fibroblasts. Genes Dev 1994;8:2540-51.
138. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, et al. A senescence program controlled by p53 and p16INK4a contributes to the
outcome of cancer therapy. Cell 2002;109:335-46.
139. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, et al. Oncogene-induced senescence as an initial barrier in lymphoma
development. Nature 2005;436:660-5.
140. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, et al. Tumour biology: senescence in premalignant tumours. Nature
2005;436:642.
141. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.
Nature 1983;304:596-602.
142. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with
accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
143. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, et al. Reversal of human cellular senescence: roles of the p53 and p16
pathways. EMBO J 2003;22:4212-22.
144. Mu XC, Staiano-Coico L, Higgins PJ. Increased transcription and modified growth state-dependent expression of the plasminogen
activator inhibitor type-1 gene characterize the senescent phenotype in human diploid fibroblasts. J Cell Physiol 1998;174:90-8.
145. McConnell BB, Starborg M, Brookes S, Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in
early passage human diploid fibroblasts. Curr Biol 1998;8:351-4.
146. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
147. Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 1986;67:257-67.
148. Braumüller H, Wieder T, Brenner E, Assmann S, Hahn M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature
2013;494:361-5.
149. Bragado P, Sosa MS, Keely P, Condeelis J, Aguirre-Ghiso JA. Microenvironments dictating tumor cell dormancy. Recent Results Cancer
Res 2012;195:25-39.
150. Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis
2009;26:51-60.
151. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, et al. Real-time imaging reveals the single steps of brain
metastasis formation. Nat Med 2010;16:116-22.
152. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.